PCIB PCI Biotech Holding ASA

Notice of Annual General Meeting 2025

Notice of Annual General Meeting 2025

Oslo, Norway, 30 April 2025 - The annual general meeting of PCI Biotech Holding ASA will be held at the company’s office at Oslo Cancer Cluster Innovation Park on 22 May 2025 at 10:00am (CEST).

The notice and proposed resolutions to the annual general meeting are attached. The notice, including all appendices, will be made available at PCI Biotech's corporate website .

For further information, please contact:

Ronny Skuggedal, CEO/CFO, E-mail:

Office: Mobile:

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

Attachments



EN
30/04/2025

Underlying

PCIBPCI Biotech Holding ASA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on PCI Biotech Holding ASA

 PRESS RELEASE
Free
PCIB PCI Biotech Hol...

PCI Biotech update on future operations

PCI Biotech update on future operations Oslo (Norway), 25 September 2025 – PCI Biotech (OSE:PCIB) today announces an update on the ongoing evaluation of its future operations. Reference is made to the announcement on 18th August 2025 regarding the discontinuation of further development of the PCL technology. The decision was based on insufficient progress, which extended project timelines and increased resource requirements, elevating the overall project risk to an unacceptable level. Consequently, PCI Biotech decided to discontinue further development. PCI Biotech's immediate priority ha...

September 25, 2025 1 EN
 PRESS RELEASE
Free
PCIB PCI Biotech Hol...

PCI Biotech half-year interim 2025 report

PCI Biotech half-year interim 2025 report Oslo (Norway), 29 August 2025 – PCI Biotech (OSE: PCIB), today announces its half-yearly 2025 interim report. Please find enclosed the interim report and presentation. Highlights review OperationsPCI Biotech decided on 18th August 2025 to discontinue further development of the PCL technology. The decision was primarily based on, as described in a press release the same day, insufficient progress towards the 2025 goal of demonstrating improved net yield at mini benchtop bioreactor scale. Achieving successful results at this scale was a critical ris...

August 29, 2025 1 EN
 PRESS RELEASE
Free
PCIB PCI Biotech Hol...

PCI Biotech: Invitation to first half 2025 results presentation and co...

PCI Biotech: Invitation to first half 2025 results presentation and corporate update Oslo, Norway, 26 August 2025 - PCI Biotech (OSE: PCIB) invites to a webcast presentation of the company's first half 2025 interim report on Friday, 29 August 2025, 08:30am – 09:00am CET (local time).  The presentation will be held in Norwegian as a live webcast available through There will be a Q&A session at the end of the presentation. Please submit questions to prior to the webcast. It will be possible to post written questions through the webcast console during the session. The interim report and ...

August 26, 2025 1 EN
 PRESS RELEASE
Free
PCIB PCI Biotech Hol...

Flaggemelding

Flaggemelding Hawkeye Invest AS, et selskap som kontrolleres av Øystein Barmen, har i dag solgt 2 000 000 aksjer i PCI Biotech Holding ASA. Etter handelen eier Hawkeye Invest AS ingen aksjer i PCI Biotech Holding ASA.

August 22, 2025 1 EN
 PRESS RELEASE
Free
PCIB PCI Biotech Hol...

Flaggemelding

Flaggemelding Hawkeye Invest AS, et selskap som kontrolleres av Øystein Barmen, har i dag kjøpt 240 000 aksjer i PCI Biotech Holding ASA. Etter handelen eier Hawkeye Invest AS 2 000 000 aksjer, noe som utgjør 5,36% av aksjene i PCI Biotech Holding ASA.

August 22, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch